Clinical Trial

STOP-HAE: A Phase 3 Study of ADX-324 in HAE

Name: STOP-HAE: A Phase 3 Study of ADX-324 in HAE — clinical trial record (NCT06960213)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: STOP-HAE

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

This study will evaluate the efficacy and safety of ADX-324 in participants with Type 1 or Type 2 hereditary angioedema. The study will also evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD), and health-related quality of life measures.

Protocol Amendment History 1 change

notable Trial sites expanded: 14 -> 50 locations 2026-04-23

Trial Details

NCT Number	NCT06960213
Lead Sponsor	ADARx Pharmaceuticals, Inc.
Conditions	Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2
Enrollment	90 participants
Start Date	2025-08-28
Primary Completion	2027-06-30 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-16